Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 118
Filter
2.
Laryngoscope ; 112(12): 2211-9, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12461343

ABSTRACT

OBJECTIVE: To examine safety aspects and vocal fold function after vocal fold augmentation with a cross-linked hyaluronan derivative (hylan B gel) as compared with bovine collagen. STUDY DESIGN; A prospective, randomized trial. METHODS: Eighty-three patients with glottal insufficiency were treated with injection augmentation with hylan B gel and bovine collagen and were examined at 1, 6, and 12 months after treatment. Seventy patients with unilateral vocal fold paresis (n = 35) or atrophy (n = 35) were randomly assigned to receive either hylan B gel (n = 47) or collagen (n = 23) injections into one vocal fold. Thirteen patients with glottal insufficiency caused by scar defects or paresis resulting from malignant disease were included in a nonrandomized group and were treated only with hylan B gel. Evaluations were made from patients' subjective ratings (visual analogue scales), digitized videostroboscopic measurements, phonetograms, maximum phonation time, and phonation quotients. RESULTS: Twelve months after injections, the patients' self-ratings were significantly improved for both the hylan B gel and the collagen groups. In addition, the videostroboscopic measurements showed significantly improved glottal closure for both groups. However, for the hylan B gel group, vibration amplitude and glottal area variations were preserved, and this group showed significantly less resorption at the injected vocal fold edge. Furthermore, maximum phonation time had increased significantly for the hylan B gel patients (collagen, nonsignificant). No serious adverse events were observed; three patients injected with hylan B gel had temporary inflammation at the injection site, which resolved without sequelae. CONCLUSIONS: The results showed that both hylan B gel and collagen can be safely used for injection treatment of glottal insufficiency. Both treatments resulted in significantly improved voice as rated by the patients. However, the patients treated with hylan B gel showed better vocal fold status and longer maximum phonation time at 12 months after treatment as compared with patients treated with collagen.


Subject(s)
Cellulose/therapeutic use , Collagen/therapeutic use , Hexamethonium Compounds/therapeutic use , Hyaluronic Acid/analogs & derivatives , Hyaluronic Acid/therapeutic use , Tantalum/therapeutic use , Thrombin/therapeutic use , Vocal Cord Paralysis/therapy , Vocal Cords/physiopathology , Aged , Animals , Cattle , Drug Combinations , Embolization, Therapeutic , Female , Follow-Up Studies , Glottis , Humans , Male , Prospective Studies , Safety , Time Factors
3.
Vestn Khir Im I I Grek ; 161(4): 11-6, 2002.
Article in Russian | MEDLINE | ID: mdl-12577544

ABSTRACT

The method of registration of the intraluminal pressure was used to study the function of the stomach, small intestine and sigmoid colon under conditions of partial ganglionic blockade in the first days after truncal vagotomy and resection of the stomach. It was found that benzohexonium in doses 0.1-0.3 mg/kg failed to substantially decrease the frequency of early functional motor-evacuation disorders of the "operated" stomach, but the results of using N-cholinolytic was better after truncal vagotomy than after resection of the stomach. Benzohexonium in doses 0.1-0.2 mg/kg failed to considerably stimulate the motor function of the small intestine while the doses of 0.3-0.4 mg/kg resulted in a decrease of its contractile activity. No reliable changes in the qualitative and quantitative parameters of the sigmoid colon motor function were found against the background of ganglionic blockade. So, for prevention and correction of early postoperative motor-evacuation disorders of the gastrointestinal tract the ganglionic blockade with N-cholinolytics should not be taken as a method of choice or a variant of monotherapy.


Subject(s)
Ganglionic Blockers/pharmacology , Gastrointestinal Motility/drug effects , Hexamethonium Compounds/pharmacology , Stomach/surgery , Vagotomy, Truncal , Animals , Dogs , Duodenum/drug effects , Ganglionic Blockers/administration & dosage , Ganglionic Blockers/therapeutic use , Gastrointestinal Diseases/prevention & control , Hexamethonium Compounds/administration & dosage , Hexamethonium Compounds/therapeutic use , Humans , Injections, Intramuscular , Intestine, Small/drug effects , Jejunum/drug effects , Myoelectric Complex, Migrating/drug effects , Postoperative Complications/prevention & control , Postoperative Period , Pylorus/surgery , Risk Factors , Stomach Ulcer/surgery , Telemetry , Time Factors
4.
Vestn Khir Im I I Grek ; 161(6): 16-20, 2002.
Article in Russian | MEDLINE | ID: mdl-12638485

ABSTRACT

The authors discuss facts and hypotheses on the effects of benzohexonium upon the motor activity of the intestine and the significance of N-cholinolytics for prophylactics and treatment of postoperative pareses of the gastrointestinal tract. The ganglioblockers possess antistress effect, reduce the degree of pathological vegetative reactions and facilitate realization of the mechanisms of selfregulation of functions of the small and large intestine. Using benzohexonium during operation and in the first days after it makes the intestinal pareses less frequent. N-cholinolytics however do not have a considerable stimulating influence on the contracting activity of the gastrointestinal tract that accounts for their not high effectiveness in treatment of early functional motor evacuatory disorders. The points of action of gangliolytics, those at the level of the intestinal wall included, can not be considered to be completely established, as well as the mechanisms of their indirect effect. The ganglionic blockade should be considered as the basic method of prophylactics of the postoperative paresis of the intestine.


Subject(s)
Abdomen/surgery , Ganglionic Blockers/pharmacology , Gastrointestinal Motility/drug effects , Hexamethonium Compounds/pharmacology , Intestinal Pseudo-Obstruction/prevention & control , Postoperative Complications/prevention & control , Animals , Cats , Colonic Pseudo-Obstruction/prevention & control , Dogs , Ganglionic Blockers/administration & dosage , Ganglionic Blockers/therapeutic use , Hexamethonium Compounds/administration & dosage , Hexamethonium Compounds/therapeutic use , Humans , Intestine, Small/drug effects , Time Factors
5.
Am J Manag Care ; 7(10): 981-91, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11669362

ABSTRACT

OBJECTIVES: To illustrate the current cost of treating osteoarthritis (OA) of the knee and to demonstrate potential savings associated with the new treatment modality of viscosupplementation in a managed care setting. STUDY DESIGN: Pharmacoeconomic model with inputs obtained from peer-reviewed medical literature, clinical trial data, clinical expert opinion, and claims data. METHODS: A spreadsheet-based model was developed to define a treatment pathway for OA of the knee, illustrate the current costs of treating patients with the condition, and demonstrate the potential savings associated with introduction of Hylan G-F 20. A hypothetical cohort of patients categorized as having mild, moderate, or severe OA of the knee was followed over a 3-year time period. The analysis was conducted from the perspective of a managed care plan with a large Medicare population. RESULTS: The 3-year savings associated with adding 1 or more courses of Hylan G-F 20 therapy to the standard treatment pathway for OA of the knee was $8,810,771. The total savings per OA patient receiving Hylan G-F 20 was $4706. The number of total knee replacements (TKRs) avoided was 808. The model was highly sensitive to the durability of Hylan G-F 20; increasing and decreasing durability within a reasonable range resulted in 3-year savings of $9,131,879 and $2,012,082, respectively. CONCLUSIONS: Hylan G-F 20 has proven to be an effective treatment for patients with OA of the knee. Appropriate use of Hylan G-F 20 could delay the need for TKRs and generate savings in the managed care setting.


Subject(s)
Biocompatible Materials/therapeutic use , Health Care Costs , Hyaluronic Acid/analogs & derivatives , Hyaluronic Acid/therapeutic use , Managed Care Programs/economics , Osteoarthritis, Knee/economics , Osteoarthritis, Knee/therapy , Adult , Aged , Aged, 80 and over , Biocompatible Materials/economics , Cellulose/therapeutic use , Cohort Studies , Cost Savings , Drug Combinations , Female , Hexamethonium Compounds/therapeutic use , Humans , Hyaluronic Acid/administration & dosage , Injections, Intra-Articular , Male , Middle Aged , Models, Econometric , Synovial Fluid/drug effects , Tantalum/therapeutic use , Thrombin/therapeutic use , United States
6.
Facial Plast Surg ; 16(1): 29-34, 2000.
Article in English | MEDLINE | ID: mdl-11802343

ABSTRACT

Soft tissue augmentation materials have been advocated for correction of post-surgical or post-traumatic facial defects, as well as for age-related folds and wrinkles. While autogenous tissues may be the safest option, they require a second operative site. Animal-derived or synthetic materials have been advocated since the late 19th century, and have waxed and waned in popularity. In recent years, we have gained a better understanding of the physical events that occur when material is placed within or below the skin. With this knowledge, we stand at the threshold of a new era, where soft tissue fillers can be designed and customized to suit the individual patient. This article will review the major materials that have been or are now advocated for use as soft tissue fillers, and will detail their relative strengths and weaknesses in order to give the clinician a better perspective when considering a material for soft tissue augmentation.


Subject(s)
Biocompatible Materials/therapeutic use , Face/surgery , Hyaluronic Acid/analogs & derivatives , Plastic Surgery Procedures/methods , Adipose Tissue/transplantation , Aminocaproates/therapeutic use , Biocompatible Materials/administration & dosage , Biocompatible Materials/chemistry , Cellulose/therapeutic use , Collagen/therapeutic use , Drug Combinations , Facial Injuries/surgery , Fibroblasts/transplantation , Gelatin/therapeutic use , Hexamethonium Compounds/therapeutic use , Humans , Hyaluronic Acid/therapeutic use , Injections, Subcutaneous , Polymers/therapeutic use , Polymethyl Methacrylate/therapeutic use , Silicone Oils/administration & dosage , Silicone Oils/chemistry , Silicone Oils/therapeutic use , Skin Aging , Tantalum/therapeutic use , Thrombin/therapeutic use
7.
Clin Ther ; 21(9): 1549-62, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10509850

ABSTRACT

The objective of this 12-week, double-masked, randomized, multicenter study was to compare the elastoviscous properties of a high-molecular-weight viscosupplement, hylan G-F 20 (polymer concentration, 0.8%), with those of a lower-molecular-weight hyaluronan (LMW HA) product (polymer concentration, 1%) and to determine the relationship of elastoviscosity to efficacy in the treatment of patients with osteoarthritis (OA) of the knee. Patients had radiographically confirmed primary idiopathic OA of the knee (Larsen grades I to V) with pain despite other treatments. After a 2-week washout period, 70 patients (73 knees) received three 2-mL intra-articular injections of test solution at 1-week intervals. Thirty-eight patients (38 knees) received hylan G-F 20, and 32 patients (35 knees) received LMW HA. During the 12-week follow-up period, the primary outcome measures assessed by patients (using a visual analogue scale) were weight-bearing pain, most painful knee movement, and overall treatment response; the primary outcome measures assessed by study evaluators were weight-bearing pain and overall assessment of treatment. The dynamic elastoviscous properties of the test solutions were measured on an oscillating Couette-type rheometer. Hylan G-F 20 was more elastoviscous than the LMW HA at all frequencies measured (0.001 to 10 Hz). At the final evaluation, patients who received hylan G-F 20 had significantly better results on all primary outcome measures compared with those who received LMW HA. No systemic adverse events were reported. Local adverse events consisted of pain or swelling, noted in 2 of 38 knees injected with hylan G-F 20, and pain, noted in 1 of 35 knees injected with LMW HA (adverse event rates per injection, 1.8% and 0.9%, respectively). The difference in the incidence of adverse events between groups was not statistically significant. The higher-molecular-weight, more elastoviscous hylan G-F 20 had significantly greater pain-relieving effects than did the lower-molecular-weight, less elastoviscous hyaluronan.


Subject(s)
Cellulose/therapeutic use , Hexamethonium Compounds/therapeutic use , Hyaluronic Acid/analogs & derivatives , Hyaluronic Acid/therapeutic use , Joint Diseases/therapy , Knee Joint , Osteoarthritis/therapy , Polymers/chemistry , Tantalum/therapeutic use , Thrombin/therapeutic use , Adult , Aged , Double-Blind Method , Drug Combinations , Elasticity , Female , Humans , Hyaluronic Acid/administration & dosage , Injections, Intra-Articular , Male , Middle Aged , Molecular Weight , Pain Measurement , Time Factors , Treatment Outcome , Viscosity
8.
Vestn Khir Im I I Grek ; 154(2): 49-52, 1995.
Article in Russian | MEDLINE | ID: mdl-8540188

ABSTRACT

Main pathogenic factors of postvagotomy diarrhea are considered. Among them are: rapid emptying of the stomach due to the draining operation and accelerated passage of chyme along the small intestine, development of a relative insufficiency of digestion and absorption, entrance of the hyperosmolar content into the colon. Diarrhea appears more often after truncal vagotomy, is paroxysmal, then in time regresses and is successfully treated with benzohexamethonium and diet. Surgical correction as the inversion of the segment of the small intestine or restoration of the pyloric sphincter is required in single cases with critical continuously recurring form of diarrhea.


Subject(s)
Diarrhea/etiology , Postoperative Complications/etiology , Vagotomy/adverse effects , Animals , Combined Modality Therapy , Defecation , Diarrhea/physiopathology , Diarrhea/therapy , Dogs , Ganglionic Blockers/therapeutic use , Gastrointestinal Transit , Hexamethonium Compounds/therapeutic use , Humans , Intestinal Absorption , Postoperative Complications/physiopathology , Postoperative Complications/therapy
9.
Anesthesiology ; 80(3): 595-605, 1994 Mar.
Article in English | MEDLINE | ID: mdl-7908178

ABSTRACT

BACKGROUND: Some reports suggest that activation of the autonomic nervous system by bupivacaine could participate in its cardiotoxicity. This is based in part on the fact that hexamethonium suppresses cardiac disturbances in anesthetized rabbits given small intracerebroventricular doses of bupivacaine. The aims of the current study were to determine, in anesthetized dogs, (1) whether the activation of the autonomic nervous system is deleterious after a large intravenous dose of bupivacaine and (2) whether the parasympathetic or sympathetic system is implicated in the bupivacaine-induced deleterious activation of the autonomic nervous system. METHODS: We used an electrophysiologic model in closed-chest dogs anesthetized with sodium pentobarbital. In group 1 (n = 6), dogs were given 4 mg/kg intravenous bupivacaine over 10 s. In group 2 (n = 6), dogs were given the same dose of bupivacaine 5 min after having received 0.2 mg/kg intravenous atropine sulfate. In group 3 (n = 9), dogs were pretreated with 10 mg/kg intravenous hexamethonium and then given bupivacaine 4 mg/kg. In addition, in group 3, the right atrium was paced at a basic cycle length of 400 ms to obtain a heart rate similar to that of group 1. RESULTS: Bupivacaine in group 1 induced significant bradycardia; lengthening of PR, atria-His, His-ventricle, and QTc intervals; and QRS widening. The first derivative of left ventricular pressure was significantly decreased, whereas left ventricular end-diastolic pressure was increased. Atropine pretreatment did not modify cardiac disturbances induced by bupivacaine. Hexamethonium pretreatment induced significantly less QRS widening and QTc lengthening than was seen in group 1 but worsened the bupivacaine effects on bradycardia, atria-His and PR intervals, mean aortic pressure, and first derivative of left ventricular pressure. Moreover, atrial pacing in group 3 induced alterations of QRS similar to those in group 1. CONCLUSIONS: Considering that marked slowing of ventricular conduction velocity (i.e., QRS widening) is known to facilitate reentrant ventricular arrhythmias, we conclude that (1) the activation of the autonomic nervous system by bupivacaine is not as deleterious as previously suggested; (2) the parasympathetic system is not markedly implicated in the worsening of direct bupivacaine cardiotoxicity; and (3) the sympathetic nervous system acts only by inducing a less marked bradycardia, which slows ventricular conduction velocity in a use-dependent manner, facilitating reentrant arrhythmias.


Subject(s)
Antihypertensive Agents/therapeutic use , Bupivacaine/toxicity , Heart Diseases/chemically induced , Heart Diseases/prevention & control , Hexamethonium Compounds/therapeutic use , Anesthesia , Animals , Atrial Function , Atropine/pharmacology , Bupivacaine/blood , Cardiac Pacing, Artificial , Dogs , Dose-Response Relationship, Drug , Electrocardiography/drug effects , Electrophysiology , Female , Heart/drug effects , Heart/physiology , Heart Atria/drug effects , Heart Conduction System/drug effects , Heart Conduction System/physiology , Heart Rate/drug effects , Hexamethonium , Male , Models, Biological , Parasympathetic Nervous System/drug effects , Parasympathetic Nervous System/physiology , Pentobarbital , Sodium Channels/drug effects
10.
Rev. méd. hered ; 4(2): 58-61, jun. 1993. ilus, tab
Article in Spanish | LILACS, LIPECS | ID: lil-156975

ABSTRACT

La administración endovenosa del veneno del escorpión B. eupeus (a dosis de 0.25 mg/Kg) incrementa la secreción gastrica de acido y pepsinógeno en la rata, sin influenciar el volumen secretado. Ambas secreciones de acido y pepsinógeno fueron inhibidas por la atropina y la vagotomia. La secreción gastrica de ácido fue incrementada por el veneno de escorpion y este efecto fue disminuido por el tratamiento con cimetidina y hexamethonium. Los efectos del veneno de B. eupeus sobre la secreción gástrica de la rata son debidas a un efecto neurotoxico a nivel pre y postganglionar parasimpático


Subject(s)
Animals , Rats , Gastric Juice , Gastric Juice , Scorpion Venoms , Atropine/therapeutic use , Vagotomy , Cimetidine/administration & dosage , Cimetidine/therapeutic use , Pepsinogen A , Hexamethonium Compounds/therapeutic use , Neurotoxins/adverse effects , Gastric Acid , Scorpion Venoms/administration & dosage , Scorpion Venoms/chemistry , Scorpion Venoms/toxicity
11.
J Biomed Mater Res ; 25(6): 699-710, 1991 Jun.
Article in English | MEDLINE | ID: mdl-1874755

ABSTRACT

Viscoelastic, pseudoplastic, radiopaque injectable hylan gel for percutaneous embolization was developed and evaluated by in vitro and in vivo tests. The embolization gel is composed of cross-linked hylan (hyaluronan, hyaluronate), tantalum, microcrystalline cellulose, hexamethonium chloride, and thrombin. Upon delivery through small-lumen catheters to the appropriate vascular site, the gel induces formation of a solid blood/gel coagulum. Results from animal studies (rat aorta, rabbit auricular artery) demonstrate that formation of complete and long-lasting arterial blockage is readily achievable without complications due to blood flow, partial vessel obstruction, uncontrolled polymerization, or movement of the gel or its components (specifically thrombin and hexamethonium chloride) into the circulation. Microscopic evaluation indicates that arterial occlusion initially occurs as a result of the injected gel and formed fibrin; at 7 weeks and beyond, arteries are occluded by injected gel, inflammatory cells and fibrosis (scar tissue).


Subject(s)
Aorta, Thoracic/physiology , Biocompatible Materials , Blood Coagulation/drug effects , Cellulose/therapeutic use , Embolization, Therapeutic , Femoral Artery/physiology , Hexamethonium Compounds/therapeutic use , Hyaluronic Acid/analogs & derivatives , Tantalum/therapeutic use , Thrombin/therapeutic use , Animals , Aorta, Thoracic/cytology , Cell Line , Cell Survival/drug effects , Cellulose/pharmacology , Drug Combinations , Elasticity , Female , Femoral Artery/cytology , Hexamethonium Compounds/pharmacology , Humans , Hyaluronic Acid/pharmacology , Hyaluronic Acid/therapeutic use , Rabbits , Tantalum/pharmacology , Thrombin/metabolism , Thrombin/pharmacology , Viscosity
12.
Pharmacol Biochem Behav ; 34(4): 817-21, 1989 Dec.
Article in English | MEDLINE | ID: mdl-2576144

ABSTRACT

Tail-tremor induced by repeated and daily administration (0.5 mg/kg SC x 6 times/day) of nicotine as well as effects of various drugs on this response were investigated in Wistar strain male rats. Daily administration of nicotine in doses of 0.5 mg/kg SC caused tail-tremors to appear beginning on the 3rd day. Tail-tremor induced by the first injection of each day gradually increased with the daily injections, however, the heightened effect of this first injection at the beginning of each day decreased during the day upon repeated administration of 6 times/day at 2-hr intervals. Basically, tail-tremor appeared about 5 min after SC administration of nicotine and reached a peak approximately 7-9 min after injection, declining to zero afterwards. Different drugs showed various effects on this response. While mecamylamine (0.5 and 1.0 mg/kg IP) abolished nicotine-induced tail-tremor, arecoline (0.5 and 1.0 mg/kg IP), atropine (2.5 and 5.0 mg/kg IP), scopolamine (1.0 and 2.0 mg/kg IP) and hexamethonium (0.5 and 1.0 mg/kg IP) showed no such effects. Furthermore, physostigmine (0.1 mg/kg IP) actually potentiated this action. These results suggest that tail-tremor induced by nicotine may be mediated through central nicotine receptor system.


Subject(s)
Nicotine/toxicity , Tremor/chemically induced , Animals , Arecoline/therapeutic use , Atropine/therapeutic use , Hexamethonium , Hexamethonium Compounds/therapeutic use , Male , Mecamylamine/therapeutic use , Nicotine/administration & dosage , Nicotine/antagonists & inhibitors , Physostigmine/therapeutic use , Rats , Rats, Inbred Strains , Scopolamine/therapeutic use , Tail , Tremor/drug therapy
14.
Biull Eksp Biol Med ; 105(4): 412-4, 1988 Apr.
Article in Russian | MEDLINE | ID: mdl-3129043

ABSTRACT

The adrenergic section of the vegetative pancreatic innervation has been examined, using morphological, histochemical and biochemical methods, during neurogenic injury, acute experimental pancreatitis and alloxan diabetes. It has been established that the development of those etiologically different processes was accompanied by catecholamine level reduction in the adrenergic structures of the pancreas which can be prevented by ganglioblockers. It is concluded that sympathetic nervous system participates in etiopathogenesis of a number of pancreatic diseases and that it is possible to prevent and treat them with sympathotropic agents.


Subject(s)
Adrenergic Fibers/physiopathology , Pancreas/innervation , Pancreatic Diseases/physiopathology , Animals , Atropine/therapeutic use , Dihydroxyphenylalanine/therapeutic use , Hexamethonium Compounds/therapeutic use , Male , Norepinephrine/metabolism , Pancreatic Diseases/prevention & control , Phenoxybenzamine/therapeutic use , Phosphocreatine/metabolism , Propranolol/therapeutic use , Rabbits , Rats
19.
Article in Russian | MEDLINE | ID: mdl-3495085

ABSTRACT

In a series of 118 patients with the Charcot-Marie-Tooth neural amyotrophy the authors evaluated a comparative therapeutic efficacy of electrophoresis of benzohexamethonium and a new method of physiotherapy, namely, administration of ganglioblockers with the help of sinusoidal modulated currents. The results of the treatment were assessed from the time course of clinico-electrophysiologic parameters. The most marked positive course of the clinico-electrophysiological parameters was observed following electrophoresis of benzohexamethonium by sinusoid modulated current.


Subject(s)
Charcot-Marie-Tooth Disease/therapy , Hexamethonium Compounds/therapeutic use , Muscular Atrophy/therapy , Physical Therapy Modalities , Adolescent , Adult , Charcot-Marie-Tooth Disease/diagnosis , Combined Modality Therapy , Electric Stimulation Therapy , Electromyography , Female , Hexamethonium Compounds/administration & dosage , Humans , Iontophoresis , Male , Massage , Middle Aged , Rheology
SELECTION OF CITATIONS
SEARCH DETAIL
...